Zoetis Inc. with ticker code (ZTS) now have 15 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $248.00 and $172.12 calculating the mean target price we have $217.58. Now with the previous closing price of $191.53 and the analysts are correct then we can expect a percentage increase in value of 13.6%. The 50 day MA is $185.63 and the 200 day moving average is $180.26. The market capitalization for the company is 88.29B. Currently the stock stands at: $194.87 USD
The potential market cap would be $100,293,831,193 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 38.14, revenue per share of $19.46 and a 14.41% return on assets.
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
